News Releases

GLI

September 1, 2016
GlycoBiomarker Leading Innovation Co. Ltd.

Participation in the Development of Advanced Measurement and Analysis Systems Program (AMED) as a co-Investigator


GL-i joins the Development of Advanced Measurement and Analysis Systems Program of the Japan Agency for Medical Research and Development (AMED) "Development of a diagnostic method for cerebrospinal fluid leak using a cerebrospinal fluid-derived marker (Project leader: Prof. Yasuhiro Hashimoto, Fukushima Medical University)" to take responsibility for the sub-theme "Optimization of brain-type transferrin assay system and analysis of clinical samples".



Project summary

Consigner: Japan Agency for Medical Research and Development (AMED)
Consignee: Fukushima Medical University
Principle investigator
(Project leader):
Yasuhiro Hashimoto, Professor
Department of Biochemistry, School of Medicine, Fukushima Medical University
Program title: Medical Research and Development Programs Focused on Technology Transfers: Development of Advanced Measurement and Analysis Systems (AMED-SENTAN)
Project theme: Development of a diagnostic method for cerebrospinal fluid leak using a cerebrospinal fluid-derived marker
Sub-theme: Optimization of brain-type transferrin assay system and analysis of clinical samples
Project term September 1, 2016 to March 31, 2019
Co-investigator
(Sub-theme leader)
Atsushi Kuno (CTO and Glycodiagnostics R&D Group)


Related Links

About the program (link to the AMED website)

Fukushima Medical University, Press release (Japanese)



Contact information

GlycoBiomarker Leading Innovation Co. Ltd. (GL-i)
1-1-1 Umezono, Tsukuba, Ibaraki 305-8568 Japan
E-mail: info@gl-i.co.jp / URL: http://www.gl-i.co.jp/en/index_e.html


Page Top